Cantor Fitzgerald started coverage on shares of Geron (NASDAQ:GERN) in a research note issued to investors on Thursday, BenzingaRatingsTable reports. The brokerage issued an overweight rating and a $4.00 price target on the biopharmaceutical company’s stock.
GERN has been the subject of several other research reports. ValuEngine raised shares of Geron from a hold rating to a buy rating in a report on Saturday, August 10th. BidaskClub downgraded shares of Geron from a hold rating to a sell rating in a report on Thursday, June 13th. Finally, B. Riley increased their price objective on shares of Geron from $3.25 to $4.50 and gave the company a buy rating in a report on Friday, June 28th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock presently has an average rating of Buy and an average target price of $3.46.
GERN opened at $1.41 on Thursday. The firm has a 50-day simple moving average of $1.29 and a two-hundred day simple moving average of $1.51. Geron has a 52 week low of $0.95 and a 52 week high of $6.99. The company has a market capitalization of $261.91 million, a PE ratio of -8.81 and a beta of 2.59.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. raised its stake in Geron by 7.9% during the 4th quarter. BlackRock Inc. now owns 15,038,176 shares of the biopharmaceutical company’s stock worth $15,037,000 after buying an additional 1,102,419 shares during the period. Northern Trust Corp raised its stake in Geron by 5.2% during the 4th quarter. Northern Trust Corp now owns 2,167,955 shares of the biopharmaceutical company’s stock worth $2,168,000 after buying an additional 106,448 shares during the period. Geode Capital Management LLC raised its stake in Geron by 4.2% during the 4th quarter. Geode Capital Management LLC now owns 1,892,556 shares of the biopharmaceutical company’s stock worth $1,892,000 after buying an additional 76,135 shares during the period. Millennium Management LLC raised its stake in Geron by 242.5% during the 4th quarter. Millennium Management LLC now owns 736,307 shares of the biopharmaceutical company’s stock worth $736,000 after buying an additional 1,253,007 shares during the period. Finally, Amalgamated Bank purchased a new stake in shares of Geron in the fourth quarter worth approximately $25,000. 31.06% of the stock is owned by institutional investors and hedge funds.
Geron Company Profile
Geron Corporation, a clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies.
Featured Article: What is an SEC Filing?
Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.